Bacterial Gastroenteritis Treatment & Management

  • Author: Jennifer Lynn Bonheur, MD; Chief Editor: Julian Katz, MD   more...
 
Updated: Apr 15, 2011
 

Medical Care

Because most infectious diarrhea is self-limited, medical care is primarily supportive in nature. Oral rehydration is the mainstay of treatment. Young infants and neonates are at high risk for secondary complications and require close monitoring, as do older individuals. Consider intravenous rehydration when oral rehydration is unsuccessful. Particular attention must be paid to repletion of potassium as needed.

  • Oral rehydration therapy is the cornerstone of diarrhea treatment, especially for small bowel infections that produce a large volume of watery stool output. Studies confirm that early refeeding hastens recovery. Many commercial oral rehydration formulas are available and have been designed to promote optimal absorption of nutrients. Administer maintenance fluids plus replacement of losses to ill children. Administer small amounts of fluid at frequent intervals in order to minimize discomfort and vomiting. A 5- or 10-cc syringe without a needle is a very useful tool. The syringe can be used to place small amounts of fluid in the mouth quickly. Once the patient becomes better hydrated, cooperation improves enough for the patient to take small sips from a cup. This method is time intensive and requires dedication. Encouragement from the physician is necessary to promote compliance.
  • Antimicrobial therapy is indicated for some bacterial gastroenteritis infections. However, many conditions are self-limited and do not require therapy. The following is a list of standard therapies:
    • Aeromonas species - Use cefixime and most third-generation and fourth-generation cephalosporins.
    • Bacillus species - No antibiotics are necessary for self-limited gastroenteritis, but vancomycin and clindamycin are first-line drugs for severe disease.
    • Campylobacter species - Erythromycin may shorten illness duration and shedding. Delaying therapy beyond 4 days from onset of symptoms appears to produce no clinical benefit.
    • C difficile - Discontinue potential causative antibiotics. If antibiotics cannot be stopped or this does not resolve diarrhea, use oral metronidazole or vancomycin. Vancomycin is reserved for seriously ill patients whose condition does not respond to metronidazole.
    • C perfringens - Do not treat with antibiotics.
    • E coli - Antibiotic treatment appears to increase the likelihood of HUS developing. Consider antibiotics if diarrhea is moderate or severe. Trimethoprim-sulfamethoxazole is a first-line drug, but use a parenteral second-generation or third-generation cephalosporin for systemic complications.
    • Listeria species - No antibiotics are needed unless invasive disease occurs. Ampicillin and Bactrim are first-line drugs for invasive disease.
    • Plesiomonas species - Use trimethoprim-sulfamethoxazole or any cephalosporin.
    • Salmonella species - Antibiotic treatment prolongs the carrier state and is associated with relapse; thus, treatment is not indicated for nontyphoid, uncomplicated diarrhea. Consider treatment for infants younger than 3 months and for high-risk patients, such as patients who are immunocompromised or who have sickle cell disease. Ampicillin is recommended for drug-sensitive strains. Trimethoprim-sulfamethoxazole, fluoroquinolones, or third-generation cephalosporins (fluoroquinolones are not recommended for use in children) are also acceptable alternatives. S typhimurium T104 is a multidrug-resistant organism. Sensitivities from the cultured specimens are important to guide therapy.
    • Shigella species - Antibiotic treatment may shorten illness duration and shedding but does not prevent complications. Most mild infections will recover without antibiotics. Moderate to severe cases should be treated with antibiotics. Ampicillin is preferred for drug-sensitive strains. For ampicillin resistant strains or in cases of penicillin allergy, trimethoprim-sulfamethoxazole is the drug of choice, although resistance does occur. Fluoroquinolones may be considered in patients with highly resistant organisms.
    • Vibrio cholerae - Tetracycline is the usual antibiotic of choice, but resistance to it is increasing. Other antibiotics that are effective when V cholerae are sensitive to them include cotrimoxazole, erythromycin, doxycycline, chloramphenicol, and furazolidone.
    • Yersinia species - Treatment (ie, trimethoprim-sulfamethoxazole, fluoroquinolones, aminoglycosides) does not shorten the disease duration and should be reserved for complicated cases.
  • Antimotility agents are not indicated routinely for infectious diarrhea, (except for refractory cases of Cryptosporidium infection).
  • Live Lactobacillus GG and heat-killed Lactobacillus LB reduce the duration of diarrhea in children when they are added to oral rehydration solution.[13, 14]
Next

Consultations

  • Certain organisms cause abdominal pain and bloody stools. Symptoms resembling appendicitis, hemorrhagic colitis, intussusception, or toxic megacolon may be appreciated. In such cases, obtain a consultation with a surgeon.
  • Consider consultation with an infectious disease specialist, especially for any patient who is immunocompromised due to human immunodeficiency virus (HIV) infection, chemotherapy, or immunosuppressive drugs, because atypical organisms are more likely and complications can be more serious and can fulminate.
Previous
Next

Diet

  • The BRAT diet (ie, bananas, rice, applesauce, toast) has been recommended for years in cases of gastroenteritis. This diet is adequate during early convalescence, but, as the patient tolerates solid food, advance the diet to provide adequate protein and caloric intake.[15, 16, 17]
  • Introduce lean meats and clear fluids as soon as possible.[15] Dairy products are said to be better absorbed when given with proteins or complex carbohydrates.
  • When feeding lactose-containing dairy products, carefully monitor patient for signs of malabsorption.
  • Breast milk contains many substances that promote bowel growth and antagonize bacteria; thus, continue breastfeeding throughout the illness for infants.
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Jennifer Lynn Bonheur, MD  Attending Physician, Division of Gastroenterology, Lenox Hill Hospital

Jennifer Lynn Bonheur, MD is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, New York Academy of Sciences, New York Society for Gastrointestinal Endoscopy, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Mukul Arya, MD  Associate Professor of Internal Medicine, Assistant Director of Therapeutic Endoscopy, Department of Gastroenterology and Internal Medicine, Wyckoff Heights Medical Center/Weill Medical College

Mukul Arya, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Medical Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Richard E Frye, MD, PhD  Assistant Professor, Departments of Pediatrics and Neurology, University of Texas Health Science Center at Houston

Richard E Frye, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, Child Neurology Society, and International Neuropsychological Society

Disclosure: Nothing to disclose.

M Akram Tamer, MD  Program Director, Professor, Department of Pediatrics, University of Miami

M Akram Tamer, MD is a member of the following medical societies: American Medical Association and Florida Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

John Gunn Lee, MD  Director of Pancreaticobiliary Service, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, University of California at Irvine School of Medicine

John Gunn Lee, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Simmy Bank, MD  Chair, Professor, Department of Internal Medicine, Division of Gastroenterology, Long Island Jewish Hospital, Albert Einstein College of Medicine

Disclosure: Nothing to disclose.

Alex J Mechaber, MD, FACP  Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD  Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

References
  1. Salminen S, Isolauri E, Onnela T. Gut flora in normal and disordered states. Chemotherapy. 1995;41 suppl 1:5-15. [Medline].

  2. Marks MI. Infectious diarrhea: introduction and commentary. Pediatr Ann. Oct 1994;23(10):526-7. [Medline].

  3. Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting, diarrhea, and dehydration. Curr Opin Pediatr. Oct 1998;10(5):461-9. [Medline].

  4. Hamer DH, Gorbach SL. Infectious diarrhea and bacterial food poisoning. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisinger and Fordtran's Gastrointestinaland Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders; 1998:1594-1632.

  5. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA. Mar 3 1999;281(9):811-7. [Medline]. [Full Text].

  6. Streit JM, Jones RN, Toleman MA, Stratchounski LS, Fritsche TR. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003). Int J Antimicrob Agents. May 2006;27(5):367-75. [Medline].

  7. World Health Organization. Cholera: fact sheet no. 107. November 2008. Available at http://www.who.int/mediacentre/factsheets/fs107/en/. Accessed February 19, 2009.

  8. Lee LA, Gerber AR, Lonsway DR, et al. Yersinia enterocolitica O:3 infections in infants and children, associated with the household preparation of chitterlings. N Engl J Med. Apr 5 1990;322(14):984-7. [Medline].

  9. Centers for Disease Control and Prevention. Yersinia enterocolitica. October 25, 2005. Available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/yersinia_g.htm. Accessed February 18, 2009.

  10. Calbo E, Freixas N, Xercavins M, Riera M, Nicolás C, Monistrol O, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis. Mar 2011;52(6):743-9. [Medline].

  11. Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. May 19 1999;281(19):1805-10. [Medline]. [Full Text].

  12. World Health Organization. Drug-resistant Salmonella: fact sheet no. 139. Revised April 2005. Available at http://www.who.int/mediacentre/factsheets/fs139/en/. Accessed February 19, 2009.

  13. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):54-60. [Medline].

  14. Simakachorn N, Pichaipat V, Rithipornpaisarn P, et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):68-72. [Medline].

  15. Duggan C, Nurko S. "Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea. J Pediatr. Dec 1997;131(6):801-8. [Medline].

  16. Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. Dec 1998;12(4):697-717. [Medline].

  17. Sullivan PB. Nutritional management of acute diarrhea. Nutrition. Oct 1998;14(10):758-62. [Medline].

  18. [Best Evidence] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al, for the Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. Jan 5 2006;354(1):11-22. [Medline]. [Full Text].

  19. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. May 2006;130(6):1588-94. [Medline].

  20. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. Nov 15 2007;64(22):2359-63. [Medline].

  21. DuPont HL, The Practice Parameters Committee of the American College of Gastroenterology. Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol. Nov 1997;92(11):1962-75. [Medline].

  22. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. Dec 2007;5(12):1418-23. [Medline].

  23. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. Aug 2006;58(2):243-55. [Medline]. [Full Text].

  24. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol. 2007;51(12):1209-14. [Medline]. [Full Text].

  25. Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am. Feb 1997;15(1):157-77. [Medline].

  26. Nataro JP, Steiner T, Guerrant RL. Enteroaggregative Escherichia coli. Emerg Infect Dis. Apr-Jun 1998;4(2):251-61. [Medline].

  27. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. Jun 2006;119(6 suppl 1):S20-8; discussion S62-70. [Medline].

  28. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. Feb 27 1999;318(7183):565-6. [Medline]. [Full Text].

  29. Trachtman H, Christen E. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Curr Opin Pediatr. Apr 1999;11(2):162-8. [Medline].

  30. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. Jun 29 2000;342(26):1930-6. [Medline]. [Full Text].

Previous
Next
 
Table 1. Stool Characteristics and Determining Their Source
Stool CharacteristicsSmall BowelLarge Bowel
AppearanceWateryMucus and/or blood
VolumeLargeSmall
FrequencyIncreasedIncreased
BloodPossibly heme-positive but never gross bloodPossibly grossly bloody
pHPossibly < 5.5>5.5
Reducing SubstancesPossibly positiveNegative
WBC count< 5/HPFPossibly >10/HPF
Serum WBC countNormalPossible leukocytosis, bandemia
OrganismsPreformed toxins:



Bacillus species, Staphylococcus aureus



Invasive bacteria:



E coli and Shigella, Salmonella, Campylobacter, Yersinia, Aeromonas, and Plesiomonas species



Toxic bacteria:



E coli, cholera, C perfringens, Vibrio species, Listeria monocytogenes



Toxic bacteria:



C difficile



Other causes:



Rotavirus, Adenovirus, Calicivirus, Astrovirus, Norwalk virus, Giardia and Cryptosporidium species



Other causes:



Entamoeba species



Table 2. Organisms and Frequency of Symptoms
OrganismIncubationDurationVomitingFeverAbdominal Pain
Aeromonas speciesNone0-2 weeks+/-+/-No
Bacillus species1-16 hours1-2 daysYesNoYes
Campylobacter species2-4 days5-7 daysNoYesYes
C difficileVariableVariableNoFewFew
C perfringens0-11 dayMildNoYes
Enterohemorrhagic E coli1-8 days3-6 daysNo+/-Yes
Enterotoxigenic E coli1-3 days3-5 daysYesLowYes
Listeria species20 hours2 daysFewYes+/-
Plesiomonas speciesNone0-2 weeks+/-+/-+/-
Salmonella species0-3 days2-7 daysYesYesYes
Shigella species0-2 days2-7 daysNoHighYes
S aureus2-6 hours1 dayYesNoYes
Vibrio species0-1 days5-7 daysYesNoYes
Y enterocolitica0-61-46 daysYesYesYes
Table 3. Common Bacteria and Optimum Culture Media
OrganismDetection MethodMicrobiological Characteristics
Aeromonas speciesBlood agarOxidase-positive, flagellated GNB
Bacillus speciesBlood agarFacultatively aerobic, spore-forming GPR; beta-hemolytic; reduces nitrates; ferments carbohydrates
Campylobacter speciesSkirrow agarRapidly motile, curved GNR; Campylobacter jejuni 90% of infections, Campylobacter coli 5% of infections
C difficileCCFE agar, EIA for toxin, LA for proteinAnaerobic, spore-forming GPR; toxin-mediated diarrhea; produces pseudomembranous colitis
C perfringensNone availableAnaerobic, spore-forming GPR; toxin-mediated diarrhea
E coliMacConkey, EMB, or SM agarLactose-producing GNR
Listeria speciesBlood agarFlagellated GPB
Plesiomonas speciesBlood agarOxidase-positive GNR
Salmonella speciesBlood, MacConkey, EMB, XLD, or HE agarNonlactose, non–H2S-producing GNR
Shigella speciesBlood, MacConkey, EMB, XLD, or HE agarNonlactose and H2S-producing GNR; verotoxin (neurotoxin)
Staphylococcus speciesBlood agarHeat-stable, preformed toxin-mediated GPC
Vibrio speciesBlood or TCBS agarOxidase-positive, motile, curved GNB
Y enterocoliticaCIN agarNonlactose-producing, oval GNR
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.